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Type2 innate lymphoid cells (ILC2s) are part of a large
family of ILCs that are important effectors in innate
immunity, lymphoid organogenesis, and tissue re-
modeling. ILC2s mediate parasite expulsion but
also contribute to airway inflammation, emphasizing
the functional similarity between these cells and Th2
cells. Consistent with this, we report that the tran-
scription factor GATA3 was highly expressed by
human ILC2s. CRTH2+ ILC2s were enriched in nasal
polyps of patients with chronic rhinosinusitis, a
typical type 2-mediated disease. Nasal polyp epithe-
lial cells expressed TSLP, which enhanced STAT5
activation, GATA3 expression, and type 2 cytokine
production in ILC2s. Ectopic expression of GATA3
in LinCD127+CRTH2 cells resulted in induction of
CRTH2 and the capacity to produce high amounts
of type 2 cytokines in response to TSLP plus IL-33.
Hence, we identify GATA3, potently regulated by
TSLP, as an essential transcription factor for the
function of human ILC2s.
INTRODUCTION
Innate lymphoid cells (ILCs) are emerging as important effectors
in innate immunity, lymphoid tissue formation, and tissue remod-
eling. ILCs are characterized by a lymphoid morphology, the
absence of markers for T, B, and myeloid cells, and high expres-
sion of the IL-7 receptor (IL-7aR; CD127). ILCs are related to
natural killer (NK) cells; they share with NK cells a dependency
on the transcriptional repressor Id2, but whereas NK cells
depend on IL-15, ILCs require IL-7 for their development and
survival (reviewed in Spits and Cupedo, 2012). IL-7-dependent
ILCs can be divided into several subpopulations on the basis
of transcription factor dependency, cytokine secretion profile,
and functions. The prototypic ILC population, lymphoid tissue
inducer (LTi) cells, is instrumental for the formation of secondary
lymphoid organs during embryonic development and depends
on the transcription factor RORgt (Eberl et al., 2004). After birth,
IL-22-producing RORgt-dependent ILCs are dominating inmucosal tissues, playing essential roles in innate immunity and
wound healing (Cella et al., 2009; Crellin et al., 2010; Satoh-
Takayama et al., 2008; Zenewicz et al., 2008).
Type 2 cytokine-producing ILCs were described by Rennick
(Fort et al., 2001) and Coffman (Hurst et al., 2002). These cells
lacked T and B cell markers, were dependent on the gamma
common (gc) chain of the IL-2 receptor, and produced high
amounts of IL-5 and IL-13 in response to the Th2 cell-stimulating
cytokine IL-25. More recently, IL-5- and IL-13-producing ILCs,
which were called natural helper (NH) cells, were found in fat-
associated lymphoid tissue where they were essential for the
innate immune response against the nematode Nippostrongulus
brasiliensis (Moro et al., 2010). These cells responded not only to
IL-25 but also IL-33. Two other research groups used IL-13
reporter mice to trace IL-25- and IL-33-responsive ILCs in
a variety of tissues including lung and gut (Neill et al., 2010; Price
et al., 2010). These IL-13-producing ILCs have been named
nuocytes (Neill et al., 2010) or innate helper type 2 (ih2) cells
(Price et al., 2010). Although some differences were noted in
phenotypes and tissue distribution of NH cells, nuocytes, and
ih2 cells, they may represent the same cell type, here referred
to as type 2 ILCs (ILC2s). Also, in humans IL-25- and IL-33-
responsive ILC2s have been defined (Monticelli et al., 2011;
Mjo¨sberg et al., 2011). These cells express CD127, the prosta-
glandin D2 receptor, chemoattractant receptor expressed on
Th2 cells (CRTH2), and the common ILC and NK cell marker
CD161 (Mjo¨sberg et al., 2011). Besides a critical role in the early
innate immune response against helminths, ILC2s are also
involved in both airway inflammation (Chang et al., 2011) and
tissue repair (Monticelli et al., 2011) after influenza virus infection.
Moreover, these ILCs can mediate type 2 disease as shown in
several mouse asthma models (Barlow et al., 2012; Bartemes
et al., 2012; Halim et al., 2012; Kim et al., 2012; Wolterink
et al., 2012). The increased presence of ILC2s in inflamed nasal
polyps of patients suffering from chronic rhinosinusitis (CRS)
(Mjo¨sberg et al., 2011) suggests an involvement of these cells in
human type 2 inflammatory diseases as well. Thus, ILC2s are
emerging as essential partners in the so-called type 2 franchise,
which include basophils, eosinophils, mast cells, Th2 cells, Th9
cells, and IgE-producing B cells, which together form the
immune response against parasites, but also mediate type 2 in-
flammatory diseases including asthma and allergic diseases
(reviewed in Oliphant et al., 2011; Paul and Zhu, 2010). TheImmunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc. 649
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TSLP and GATA3 Control the Function of ILC2svarious type 2 leukocyte populations are governed by factors
produced by hematopoietic and nonhematopoietic accessory
cells. Besides IL-25 and IL-33, these factors include thymic
stromal lymphopoetin (TSLP). TSLP is produced predominantly
by epithelial cells and is believed to prime dendritic cells (DCs)
to facilitate development of Th2 cells (Ito et al., 2005), which is
associated with the pathogenesis of allergic inflammatory
diseases (reviewed in Ziegler and Artis, 2010).
The developmental requirements and the transcription factors
that are responsible for differentiation and function of ILCs are
being unraveled. RORgt is required for development and func-
tion of LTi cells and ILC22 but is dispensable for development
of ILC2s (Moro et al., 2010; Neill et al., 2010). Instead, the related
transcription factor RAR-related orphan receptor alpha (RORa,
also known as TR1F1) is needed for ILC2s as shown by the
fact that RORa-deficient mice fail to develop ILC2s (Wong
et al., 2012). Other transcription factors that affect the function
of ILC2s have yet to be identified. The transcription GATA3might
be a candidate. GATA3 is needed for development of Th2 cells
and acts by binding directly to several genes of the Th2 cell
cytokine locus including IL4, IL5, and IL13, and concomitantly
inhibiting development of Th1 cells (Zheng and Flavell, 1997;
Ouyang et al., 1998).
Previously we noted striking similarities between ILCs and
Th cell subsets with respect to their cytokine production profiles
and proposed that ILCs and Th cells share transcriptional
programs that regulate their development and function (Spits
and Di Santo, 2011). Consistent with this hypothesis, we show
here a critical role of GATA3 in the function of human ILC2s.
Although GATA3 is broadly expressed among the different ILC
populations, including NK cells, ILC2s were characterized by
high GATA3 expression. Activation of resting ILC2s by TSLP
increased the expression of GATA3. TSLP strongly enhanced
IL-4, IL-5, and IL-13 production, activated STAT5, and acted
with IL-33 to synergistically induce IL-4, IL-5, and IL-13 produc-
tion. GATA3 was essential for the function of ILC2s, as shown
by the fact that ectopic expression of GATA3 by retrovirus-
mediated gene transfer in LinCD117+CD127+CRTH2 cells
resulted in induction of CRTH2 and in acquisition of the capacity
to produce high amounts of IL-5 and IL-13 as well as IL-4 in
response to TSLP plus IL-33. Hence, we identify GATA3 as an
essential transcription factor for the function of human ILC2s,
emphasizing the similarity of ILC2s and Th2 cells aswe proposed
earlier (Spits and Di Santo, 2011).
RESULTS
Nasal Polyp Epithelium Express IL33 and TSLP
We previously showed that ILC2s, defined as LinCD127+
CRTH2+, are strikingly enriched in inflamed nasal polyps of
CRS patients as compared to noninflamed nasal mucosa of
healthy control subjects (Mjo¨sberg et al., 2011). Further charac-
terization revealed that these ILC2s respond to IL-25 and IL-33
with increased production of IL-13 (Figure S1A available online),
a behavior characteristic of the ILC2s that we previously identi-
fied in peripheral blood and fetal gut, defined as LinCD127+
CRTH2+CD161+CD25+ (Mjo¨sberg et al., 2011). Like ILC2s in
peripheral blood, short-term primary cell lines of nasal polyp
ILC2s (henceforth referred to as ‘‘ILC2 cell lines’’) could be650 Immunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc.established that kept their surface expression of CD127 and
CRTH2 (Figure S1B). Although only a minority of these cells
produced IL-22 and IFN-g, they all produced IL-13 but no
IL-17 upon short-term culture with PMA plus ionomycin (Fig-
ure S1C), demonstrating their type 2 cytokine production profile.
ILC2 cell lines expressed receptors for IL-25 and IL-33 (Figures
S1D and S1E) and also responded to IL-25 and IL-33 in com-
bination with IL-2 in vitro (Figures S1F and S1G). These data
demonstrated that both freshly isolated and ILC2 cell lines
from nasal polyps were similar to the ILC2s that we previously
described in peripheral blood and fetal gut (Mjo¨sberg et al.,
2011). In addition, the ILC2s were characterized by expression
of CD25 (Mjo¨sberg et al., 2011) and ST2 mRNA (Figure S1E),
indicating that they are similar to those previously described by
Monticelli et al. (2011).
To broaden our understanding of the physiological stimuli
that contribute to the accumulation and maintenance of ILC2s
in the nasal polyps, we investigated nasal epithelial cells, a major
source of immune regulatory cytokines, for expression of poten-
tial ILC2-regulating cytokines. Nasal epithelial cells from healthy
individuals and CRS nasal polyps constitutively, and at compa-
rable amounts, expressed factors that were previously shown
to regulate ILC2s including IL33 (Figure 1A) and also TSLP
mRNA (Figures 1B and 1C). In this study, we analyzed both the
total TSLP transcript expression (including both the short and
long splice variants of the TSLP mRNA) and the long splice
variant of the TSLP mRNA separately, because the latter was
shown to be associated with actual TSLP protein production
(Harada et al., 2009).
It was previously demonstrated that polyinosinic:polycytidylic
acid [poly(I:C)], a double-stranded RNA analog and Toll-
like receptor (TLR) 3 ligand, induces TSLP expression in human
bronchial epithelial cells (Harada et al., 2009). We extended this
finding to also include nasal epithelial cells, because poly(I:C)
upregulated the expression of long-form TSLP, as well as IL33,
in nasal polyp epithelial cells, nasal epithelial cells from healthy
individuals, and the respiratory airway epithelial cell line H292
(Figures 1A and 1B). IL33 and long-form TSLP were not selec-
tively induced by poly(I:C); stimulation with flagellin, R848, and
PGN also resulted in an increase in IL33 and long-form TSLP
expression (Figures 1D and 1E).
In summary, these data show that nasal epithelial cells from
both healthy nasal mucosa and CRS polyps constitutively, and
at similar amounts, express both total and long-form TSLP,
which is induced by a wide range of TLR ligands. Collectively,
this means that nasal epithelial cells are able to respond to
microbial challenge by producing factors, including IL-33 and
TSLP, known to be involved in the type 2-mediated inflammation
seen in these nasal polyps (van Drunen et al., 2012).
ILC2s Respond to TSLP Expressed by Nasal Polyp
Epithelium
Having identified TSLP as an immune regulatory cytokine ex-
pressed by nasal epithelial cells, we hypothesized that TSLP
could have the capacity to induce cytokine production from
ILC2s, similar to what was previously described for IL-33.
TSLP signals through a receptor heterodimer consisting of the
TSLP receptor and the IL-7 receptor a chain (CD127), the latter
being constitutively expressed by all subsets of human and
Figure 1. TSLP and IL-33 Are Expressed by Nasal Epithelial Cells
(A–C) Nasal epithelial cells from CRS polyps (filled dots), healthy mucosa (open squares), or H292 airway epithelial cells lines (open triangles) were cultured with
poly(I:C) and analyzed for expression of IL33 (A), long-form TSLP (B), and total TSLP (C) mRNA by RT-PCR.
(D–F) Nasal epithelial cells from healthy mucosa was analyzed for IL33 (D), long-form TSLP (E), and total TSLP (F) by RT-PCR.
Expression was normalized to expression of the house-keeping geneGAPDH and to the expression of unstimulated cells to generate the relative expression ratio
at each time point. All data are shown as mean ± SD and are representative of at least two independent experiments performed in triplicate.
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TSLP and GATA3 Control the Function of ILC2smouse ILCs. Analyzing the expression of the TSLP receptor
(TSLPR) subunit, we found a high expression in both freshly iso-
lated and ILC2 cell lines from tonsils, blood, and nasal polyps as
compared to other ILC subsets, including NK cells (Figures 2A
and 2B).
Consequently, stimulating freshly isolated ILC2s from blood
and nasal polyps with TSLP in combination with IL-2 resulted
in significantly increased secretion of IL-13, one of the signature
cytokines for the human ILC2s (Figures 2C and 2D). In addition,
ILC2s also produced a number of additional cytokines associ-
ated with type 2 immune responses, including IL-4, IL-5, IL-9,
and GM-CSF and the production was clearly enhanced by
IL-33, and to a lesser extent also TSLP (Figures 2C and 2D).
We also analyzed a range of other cytokines, of which the
ILC2s produced IL-6, IL-8, and IP10 at concentrations above
100 pg/ml. Many other cytokines were produced at concentra-
tions below 100 pg/ml and were not affected by IL-33 or TSLP
stimulation (see Table S1).
The fact that TSLP triggered resting ILC2s freshly isolated
from peripheral blood (Figure 2C) suggests that these cells do
not require preactivation to respond to TSLP, in contrast to
what was previously reported for Th2 cells (Kitajima et al.,
2011). Like freshly isolated ILC2s, prerested ILC2 cell lines re-
sponded to TSLP with increased IL-4, IL-5, and IL-13 production
(Figures 2E and 2F). This response was more apparent in the
presence of IL-2, and TSLP plus IL-33 exerted a strong syner-
gistic induction of IL-4, IL-5, and IL-13 production (Figures 2E
and 2F). Notably, TSLP plus IL-33 induced the expression of
ST2, an observation previously made for Th2 cells (Guo et al.,
2009), possibly explaining this synergistic effect (Figure S1H).
When following IL-33 plus TSLP response over time, we ob-
served that IL-13 was induced at day 2, before significant cell
proliferation was induced by TSLP (data not shown). Hence,
the increased IL-13 concentration seen in the supernatants afterIL-33 plus TSLP stimulation was most probably the result of
increased IL-13 production on a per cell basis rather than prolif-
eration of a subpopulation of IL-13+ cells. IL-25, especially in
combination with IL-33, triggered significant IL-13 production
from ILC2s (Figures S1F and S1G). IL-25 also acted in synergy
with TSLP to induce IL-13 production but to amuch lesser extent
than what we observe for the combination of IL-33 and TSLP
(data not shown). Hence, we focused our studies on TSLP and
IL-33, because these cytokines had the strongest effects on
the ILC2s.
Collectively, our data identify TSLP, expressed by nasal
epithelial cells, as a potent stimulator that acts in synergy with
IL-33 to induce cytokine secretion from ILC2s in nasal polyps.
TSLP Triggers STAT5 Activation that Drives IL-13
Production in ILC2s
We next asked the question which signaling pathway was
involved in TSLP-induced IL-13 production. In Th2 cells, TSLP
triggers phosphorylation of STAT5 (Kitajima et al., 2011) but
STAT3 has also been reported to be activated through TSLP
(Reche et al., 2001). Stimulating ILC2s with TSLP, IL-2, or IL-7
(data not shown) led to phosphorylation of STAT5, but not
STAT3, whereas IL-15, a known trigger of conventional NK cells,
stimulated phosphorylation of both STAT5 and STAT3 in NK cell
lines (Figures 3A and 3B). NK cells, however, did not respond to
TSLP with STAT5 phosphorylation (Figure 3A), consistent with
the low to undetectable TSLPR expression in these cells (Figures
2A and 2B).
To examine the hypothesis that STAT5 activation alone is
sufficient to drive TSLP-induced IL-13 production in ILC2s, we
made use of a tamoxifen (4HT)-inducible retroviral construct
encoding STAT5b linked to the estrogen receptor (ER) (Scheeren
et al., 2005). With this approach, activation of STAT5, but not
STAT3, in prerested ILC2s led to a clear induction of IL-13Immunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc. 651
Figure 2. ILC2s Express Receptors for and Respond to TSLP
(A and B) TSLPRmRNA expression as determined by RT-PCR in freshly isolated (A) or short-term primary cell lines (B) of ILC2s (sorted as LinCD127+CRTH2+),
NK cells (sorted as CD3CD56dim), or ILC22 cells (sorted as LinCD127+CD117+NKp44+) isolated from blood, nasal polyps, tonsil, or fetal gut as indicated in the
figure. Expression was normalized to expression of the house-keeping gene 18S and shown as mean ± SEM.
(C and D) Cytokine secretion after stimulation of freshly isolated ILC2s (sorted as LinCD127+CRTH2+) from (C) blood and (D) polyps with IL-2 plus IL-33 or IL-2
plus TSLP for 4 days. Data were normalized to 2,000 cell/200 ml and are shown as pg/ml.
Data in (A)–(D) are from at least three independent experiments with one donor each.
(E and F) Cytokine secretion after stimulation of ILC2 cell line from (E) blood or (F) nasal polyp with IL-2, IL-33, TSLP, and combinations of these cytokines as
indicated for 4 days.
Cytokine production was measured by a multiplex cytokine bead assay and shown as pg/ml. Data are representative of at least three independent experiments
with one donor each stimulated in triplicate. All data are shown as mean ± SEM. Student’s paired t test *p% 0.05, **p% 0.01, yp = 0.06, yyp = 0.07. See Figure S1
for additional information.
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TSLP and GATA3 Control the Function of ILC2sproduction (Figure 3C), showing that the isolated activation of
the STAT5 pathway is sufficient to induce IL-13 production in
ILC2s.
GATA3 Is Induced by the STAT5 Activator TSLP
One of the direct targets of STAT5 is the Th2 cell-associated
transcription factor GATA3 (Guo et al., 2009), which directly
binds to several genes of the Th2 cell cytokine locus, including652 Immunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc.IL13, to induce their transcription. To assess the role for
GATA3 in ILC2s, we first evaluated the GATA3 expression in
freshly isolated and ILC2 cell lines. Comparing GATA3 expres-
sion to other ILC subsets revealed that GATA3 was highly ex-
pressed by both freshly isolated and ILC2 cell lines (Figures 4A
and 4B). GATA3 mRNA expression was not exclusively
restricted to the ILC2 subset; ILC22 and NK cells also expressed
GATA3 (Figures 4A and 4B), the latter finding being consistent
Figure 3. TSLP Stimulates Phosphorylation of STAT5 in ILC2s
(A and B) Expression of phosphorylated STAT3 and STAT5 as measured by flow cytometry. ILC2s (sorted as LinCD127+CRTH2+) or NK (sorted as
CD3CD56dim) short-term cultured cells were rested overnight in medium without cytokines and subsequently pulsed with the indicated cytokines for 20 min.
Data are representative of three independent experiments with at least one donor each.
(C) Tamoxifen (4HT) treatment of prerested, presorted (GFP+ or GFP) peripheral blood ILC2 cell lines transduced (GFP+) with retroviral constructs encoding
STAT5b or STAT3 linked to the estrogen receptor (ER) or empty control vector (EV). Data are from two experiments with one donor each and shown as
mean ± SEM. 4HT, 4-hydroxytamoxifen.
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TSLP and GATA3 Control the Function of ILC2swith the previously described role of GATA3 as a regulator of NK
cells (Samson et al., 2003).
Having shown that TSLP triggers STAT5 activation, which
alone is sufficient to drive expression of IL-13, we investigated
the capacity of TSLP to induce GATA3 expression in ILC2s.
TSLP increased the frequency of cells expressing GATA3 protein
(Figure 4C). Furthermore, TSLP stimulation led to increased
GATA3 mRNA expression (Figure S2). NK cells also expressed
GATA3 protein but at a lower level than did ILC2s (Figure 4D).
Importantly, GATA3 expression was not triggered by TSLP in
NK cells (Figure 4D), in line with the low expression of TSLPR
on these cells (Figures 2A and 2B). Analyzing GATA3 protein
expression over time revealed that GATA3 was induced by
TSLP in nondividing cells by day 2, demonstrating that TSLP
induces expression of GATA3 protein and not preferential
outgrowth of GATA3+ cells (Figure S2).
Ectopic Expression of GATA3 Is Sufficient to Drive the
ILC2 Program
In ILC2s, TSLP induced IL-13 production in a STAT5-dependent
fashion, which also correlated with induction of GATA3. In Th2
cells, GATA3 is the master transcription factor that governs a
wide spectrum of features unique to Th2 cells, including expres-
sion of ST2, thereby making the cells responsive to IL-33 as
shown by high IL-13 production (Guo et al., 2009). To formally
test the role of GATA3 in ILC2 function, we asked whether
GATA3 overexpression is sufficient to drive the program of
ILC2 phenotype and function. Overexpression of GATA3, as
confirmed at mRNA (Figure 5A) and protein (Figure S3A) level,
in a population of LinCD127+CD117+NKp44CRTH2 ILCs
led to expression of the cardinal surface marker of ILC2s and
Th2 cells, CRTH2 (Figure 5B), suggesting that forced GATA3
expression is sufficient to induce differentiation toward the
ILC2 lineage. In strong support of this, GATA3-overexpressing
ILCs upregulated the expression of ST2 and TSLPR (Figures
5C and 5D) and also resulted in acquisition of the capacity to
respond to IL-33 plus TSLP by secreting high amounts of IL-
13, IL-4, IL-5, and GM-CSF (Figures 5E–5H). Notably, GATA3
overexpression by itself was not sufficient to drive significant
type 2 cytokine production in these cells, as indicated by thefact that GATA3-overexpressing cells rested in low amounts of
IL-2 produced only modest amounts of IL-4, IL-5, IL-13, and
GM-CSF (Figures 5E–5H). This notion is in agreement with the
observation that GATA3 alone is not sufficient to induce IL-4
production in M12 B cell lymphoma cells, which requires
additional activating signals provided by PMA plus ionomycin
(Zheng and Flavell, 1997). Hence, GATA3 most probably acts
as a transactivator of IL-4, IL-5, and IL-13 production, requiring
additional signals provided by TSLP and IL-33.
ILC2s were recently shown to depend on the transcription
factor RORa, because RORa-deficient mice lack ILC2s and fail
to expel helminth parasites in the intestine, a process normally
mediated by ILC2s (Wong et al., 2012). In agreement with these
data, we find that human ILC2s also express higher amounts of
RORA as compared to ILC22s and NK cells (Figure S3B). As
seen for GATA3, RORA expression was not exclusively restricted
to the ILC2 subset; ILC22 and NK cells also expressed RORA.
GATA3 overexpression in CRTH2 ILCs did not lead to sig-
nificant upregulation of RORA expression (Figure S3C). Further-
more, TSLP stimulation, which enhances GATA3 expression in
ILC2s, did not upregulate RORA (Figure S3D). Hence, we
conclude that RORA is not potently regulated by GATA3 and
that GATA3 can induce TSLP plus IL-33 responsiveness, result-
ing in IL-13 production independent of enhanced RORA
expression.
Silencing of GATA3 Reduces the Responsiveness
to IL-33 and TSLP in ILC2s
To determine whether GATA3 is essential for the function of
ILC2s, we investigated the functional consequences of GATA3
silencing in these cells. Transducing ILC2s with retroviral con-
structs encoding small hairpin-RNA targeting the GATA3
mRNA led to a 30%–60% reduction of GATA3+ cell frequency,
both at baseline (in the presence of low dose IL-2) and upon
stimulation with TSLP plus IL-33 (Figure 6A). At the mRNA level,
a 30% reduction in GATA3 mRNA expression was seen at
baseline (Figure S4). Even given the fact that GATA3 was only
partially silenced, the reduction in GATA3 expression had func-
tional consequences for IL-4, IL-5, and IL-13 production, as
shown by the fact that GATA3 silencing significantly reducedImmunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc. 653
Figure 4. TSLP Enhances GATA3 Expression in ILC2s
(A and B) GATA3 mRNA expression as determined by RT-PCR in freshly iso-
lated (A) or short-term primary (B) cell lines of ILC2s (sorted as LinCD127+
CRTH2+), NK cells (sorted as CD3CD56dim), or ILC22 cells (sorted as
LinCD127+CD117+NKp44+) isolated from blood, nasal polyps, tonsil, or fetal
gut as indicated in the figure. Data are from at least three independent
experiments with one donor each. Expression was normalized to expression
of the house-keeping gene 18S and shown as mean ± SEM.
(C and D) ILC2 (sorted as LinCD127+CRTH2+) (C) or NK (sorted as
CD3CD56dim) (D) short-term cell lines were stimulated with IL-2, IL-33, TSLP,
or combinations of these cytokines for 4 days and analyzed for expression of
intracellular GATA3 protein by flow cytometry.
Data are representative of three independent experiments with at least one
donor per experiment. See Figure S2 for additional information.
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TSLP and GATA3 Control the Function of ILC2sthe production of IL-13, as compared to control vector trans-
duced cells (Figures 6B–6D). This was also observed for IL-4
and IL-5, but because of the high variability in the degree of
GATA3 silencing, these differences did not reach statistical
significance. The decrease in type 2 cytokine production was
not due to reduced survival of the GATA3-silenced cells; the ratio
of GFP+ GATA3sh transduced and GFP untransduced cells
remained stable over time in transduced cultures (data not654 Immunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc.shown). These data show that even a partial silencing of
GATA3 is sufficient to affect the functionality of ILC2s, demon-
strating that GATA3 is critical for IL-33 plus TSLP responsive-
ness in terms of IL-4, IL-5, and IL-13 production.
DISCUSSION
We report here that the transcription factor GATA3 is important
for the function of human ILC2s, emphasizing the functional
similarity between ILC2s and Th2 cells. Although GATA3 is
broadly expressed among the different ILC populations,
including NK cells, ILC2s are characterized by high GATA3
expression. We previously showed that ILC2s are enriched in
nasal polyps of patients with CRS, a typical type 2-mediated in-
flammatory disease. We observed that TSLP, expression of
which is enhanced in nasal epithelial cells upon microbial chal-
lenge, is a potent regulator of ILC2s, as shown by the fact that
TSLP enhances GATA3 expression and production of a wide
range of type 2 cytokines in these cells. In contrast to Th2 cells,
this occurs without prior activation of the cells, showing that
ILC2s are able to directly respond to epithelial-derived TSLP
to initiate the type 2 response. In ILC2s, TSLP signals through
STAT5 and acts with IL-33 to synergistically induce IL-13
production. GATA3 is crucial for the function of ILC2 because
ectopic expression of GATA3 by retrovirus-mediated gene
transfer in LinCD127+CD117+NKp44CRTH2 cells results in
induction of surface CRTH2, in expression of ST2 and TSLPR,
and in acquisition of the capacity to produce high amounts of
type 2 cytokines in response to TSLP plus IL-33.
Asthma, allergic rhinitis, and atopic dermatitis are atopic
diseases where elevated levels of TSLP have been reported.
Together with the notion that TSLP polymorphisms are associ-
ated with atopy (reviewed in Ziegler and Artis, 2010) and that
TSLP receptor-deficient mice are resistant to ovalbumin-
induced asthma (Zhou et al., 2005), this suggests a role for
TSLP in the pathogenesis of these diseases. TSLP induces
polarization of dendritic cells, with increased expression of
OX40L, promoting differentiation of naive T cells to Th2 cells
(Ito et al., 2005). Th2 cells produce IL-4, IL-5, and IL-13, key cyto-
kines in allergy and asthma, indicating that TSLP is involved in
exacerbation of allergic inflammation driven by Th2 cells.
However, experimental allergen-induced asthma occurs also
in RAG-deficient mice, which lack T cells, suggesting that cells
of the innate immune system are critical effectors in type
2-mediated inflammation (Bartemes et al., 2012; Halim et al.,
2012; Wolterink et al., 2012). Indeed, several studies have
demonstrated a role for ILC2s in various models of allergic
airway inflammation (Barlow et al., 2012; Kim et al., 2012;
Wilhelm et al., 2011; Bartemes et al., 2012; Halim et al., 2012;
Wolterink et al., 2012). Furthermore, ILC2s are involved in influ-
enza virus-mediated airway hyperreactivity by promoting inflam-
mation (Chang et al., 2011). In contrast, ILC2s are also critical for
tissue repair and remodeling inflicted by influenza virus infection
(Monticelli et al., 2011). We observed that TSLP induces the
production of high amounts of IL-13 and IL-5, but also IL-4,
IL-9, and GM-CSF by ILC2s. In the mouse, it was reported that
Th2 cells express TSLP receptors and respond to TSLP by
production of the Th2 cell type cytokines IL-4, IL-5, and IL-13
(Kitajima et al., 2011), demonstrating the functional similarity
Figure 5. GATA3 Overexpression Is Sufficient to Drive the ILC2 Program
(A) LinCD127+CD117+NKp44CRTH2 cells were transduced with a retroviral vector encoding GATA3 wild-type (WT) or empty vector (EV), sorted as
transduced (GFP+) or untransduced (GFP) cells on day 3 and analyzed for GATA3mRNA expression by RT-PCR. Expression was normalized to expression of
the house-keeping gene 18S. Data are from two independent experiments with at least one donor each.
(B) CRTH2 surface expression in empty vector control transduced (left) or GATA3 overexpressing (right) cells (GFP+) as determined by flow cytometry. The
percentages within the dot plots refer to the percentage of CRTH2+ ILCs within the GFP+ gate representing transduced cells. Data are from three independent
experiments with at least one donor each.
(C and D) LinCD127+CD117+NKp44CRTH2 cells were transduced as described in (A) and analyzed for ST2 (C) or TSLPR (D) mRNA expression by RT-PCR.
Expression was normalized to expression of the house-keeping gene 18S. Data are from two independent experiments with at least one donor each.
(E–H) IL-13, IL-5, IL-4, and GM-CSF production from empty vector control (black bars) or GATA3 overexpressing (unfilled bars) cells upon IL-2 or IL-2, IL-33 plus
TSLP stimulation for 4 days. Cells were transduced and sorted as described in (A). Cytokine production was normalized to that of the EV-transduced cells and
shown as percentage of EV control. Data are from three independent experiments with at total of six donors. All data are shown as mean ± SEM. Wilcoxon’s
matched pairs test *p% 0.05, yp = 0.06. See Figure S3 for additional information.
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Figure 6. GATA3 Silencing Reduces IL-13 Production in ILC2s
(A) ILC2s (sorted as LinCD127+CRTH2+) short-term cell lines were transducedwith a retroviral vector encoding GATA3 small-hairpin (sh) or empty vector, sorted
as transduced (GFP+) or untransduced (GFP) cells on day 3, stimulated with IL-2 or IL-2, IL-33 plus TSLP for 4 days and analyzed for GATA3 protein expression
by flow cytometry. Data are from two independent experiments with at least one donor each.
(B–D) IL-13, IL-5, and IL-4 production from empty vector control (black bars) or GATA3sh (unfilled bars) cells upon IL-2 or IL-2, IL-33 plus TSLP stimulation for
4 days. Cells were transduced and sorted as described in (A). Cytokine production was normalized to that of the EV-transduced cells and shown as percentage
of EV control. Data are from four independent experiments with at total of five to eight donors. Data are shown as mean ± SEM. Wilcoxon’s matched pairs test
**p% 0.01. See Figure S4 for additional information.
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TSLP and GATA3 Control the Function of ILC2sbetween ILC2s and Th2 cells. However, TSLP responsiveness in
Th2 cells was significant only after activation via the T cell
receptor (Kitajima et al., 2011). Our data showed that freshly
isolated ILC2s from nasal polyps, but also from blood, most
probably in a resting state, respond to TSLP without prior activa-
tion. Hence, ILC2s are capable of directly responding to TSLP,
initiating the type 2-mediated response.
In search for the cellular source of TSLP in the nasal polyps, we
found that in epithelial cells, TSLP was expressed at baseline
and that expression was promoted upon stimulation with several
TLR agonists including poly(I:C), flagellin, R848, and PGN, indi-
cating that microbes might be the indirect trigger of high type 2
cytokine production by ILC2s. While completing our work, a
study of papain-induced asthma demonstrated that also in
mice, stromal-derived TSLP and IL-33 induce IL-13 production
from ILC2s, driving the allergic inflammation (Halim et al.,
2012). Thus, both in mice and humans, airway pathology may
bemediated by aberrant stimulation of epithelial cells that initiate
a cascade of reactions leading to overstimulation of ILC2s.
TSLP has been reported to signal through STAT5 (Kitajima
et al., 2011) and STAT3 (Reche et al., 2001). We found that
TSLP stimulation of ILC2s led to activation of STAT5 but not
STAT3. Consistent with our findings on ILC2s, in Th2 cells,
TSLP enhances phosphorylation of STAT5 and production of
type 2 cytokines such as IL-4, IL-5, and IL-13 (Kitajima et al.,
2011). ChIP analysis revealed that STAT5 binds directly to the
GATA3 gene (Kitajima et al., 2011), suggesting that STAT5
directly upregulates the expression of GATA3. Indeed, our
studies support this idea: the isolated activation of STAT5
alone enhanced IL-13 production in ILC2s. Hence, we identify
the TSLP signaling pathway in ILC2s as being dependent
on STAT5 and GATA3, with subsequent production of IL-13,
IL-5, and IL-4 shown to be direct targets for GATA3 (Yagi
et al., 2011).656 Immunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc.Recently, it was demonstrated that bone marrow-derived
LinCD127+Flt3 common lymphoid progenitors in the pres-
ence of Notch1, IL-7, and IL-33 signaling gave rise to ILC2s.
These cells failed to develop in mice with a spontaneous deletion
in the gene for the transcription factor RORa. Consequently,
because ILC2s are crucial for parasite expulsion in the intestine,
RORa-deficient mice failed to mount an appropriate immune
response to the helminth parasite N. brasiliensis (Wong et al.,
2012). Our data identified GATA3 as crucial for the function of
ILC2s. A recent study showed that transgenic mice where
GATA3 was deleted only in IL-13-producing cells, of which the
majority was ILC2s during N. brasiliensis infection, were pheno-
copies of IL-13-deficient mice, exhibiting reduced worm clear-
ance (Liang et al., 2012). This shows that GATA3 is critical for
IL-13 production in ILC2s. These data parallel our findings, which
identify GATA3 as crucial for the function of ILC2s. In ILC2s,
GATA3, potently induced by TSLP, seems to regulate not only
the production of type 2 cytokines in conjunction with IL-33,
possibly through NF-kB signaling, but also the expression of
ST2 and TSLPR, thereby controlling the IL-33 plus TSLP-
induced activation of these cells. Hence, GATA3 is a central
player in the function of ILC2s, emphasizing the similarity of
these cells and Th2 cells, consistent with the idea that ILC2s
and Th2 cells share not only cytokine secretion profiles, but
also transcriptional programs (Spits and Di Santo, 2011). A
critical difference between these type 2 effector cells is, how-
ever, that RORa is required for ILC2 but not for Th cell develop-
ment (Wong et al., 2012). In our studies of human ILC2s, we
find that RORA is highly expressed, but not restricted to,
ILC2s; ILC22 and NK cells also express intermediate levels
of RORA. Notably, GATA3 does not seem to control the expres-
sion of RORA, because neither ectopic nor enhancement
of endogenous GATA3 expression by TSLP induced RORA
expression. In an accompanying paper (Hoyler et al., 2012), it
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ILC2s and that during development of ILC2s from its progenitor,
high levels of GATA3 is expressed before RORa. Our studies
suggest that RORa is not regulated by GATA3. Hence, it is
possible that RORa acts in parallel with GATA3 in regulating
ILC2 development. Future studies should further unravel the
mechanisms underlying the role of RORa and GATA3 in the
development of these cells.
In conclusion, we show here that ILC2s are directly induced by
nasal stromal-derived factors such as TSLP, and we identify the
TSLP-GATA3 axis as crucial in controlling the function of these
cells. ILC2s are emerging as critical players in type 2-mediated
immune pathology in the airways. Hence, they constitute a
member of the ‘‘type 2 franchise,’’ including mast cells, baso-
phils, eosinophils, and Th2 cells that collectively mediate immu-
nity against helminth parasites but are also involved in allergy
and asthma. ILC2smay constitute an early source of type 2 cyto-
kines, capable of initiating and amplifying Th2 cell-mediated
responses. In addition, ILC2s are important for tissue repair
but may also mediate pathology. As such, ILC2s and the cyto-
kines they produce may be attractive targets for therapy of
type 2-mediated immune pathologies.
EXPERIMENTAL PROCEDURES
Collection of Human Tissues
Inflamed nasal polyps were obtained from chronic rhinosinusitis patients
during surgery and healthy nasal tissues were from nasal correction surgeries.
Tonsils were from routine tonsillectomies. All nasal and tonsil tissue collection
was done at the Academic Medical Center (AMC) (Amsterdam, The
Netherlands) and approved by the Medical Ethical Commission of the AMC.
Human fetal tissues were obtained from elective abortions at the Stichting
Bloemenhove clinic in Heemstede (The Netherlands) upon on the receipt of
informed consents. The use of human abortion tissues was approved by the
Medical Ethical Commission of the AMC. Gestational age was determined
by ultrasonic measurement of the diameter of the skull or femur and ranged
from 14 to 17 weeks. Buffy coats were provided by the blood bank at Sanquin
(Amsterdam) after written informed consent.
Isolation and Stimulation of Human Nasal Epithelial Cells
NCI-H292 human airway epithelial cells (American Type Culture Collection,
USA) were cultured at 37C in RPMI 1640 culture medium (Invitrogen, The
Netherlands) supplemented with 10% (v/v) fetal calf serum (HyClone, USA),
1.25 mM of glutamine, 100 U/ml of penicillin, and 100 mg/ml of streptomycin.
Primary epithelial cells were obtained by digestion of nasal biopsies or polyps
with 0.5 mg/ml collagenase 4 (Worthington Biochemical Corp., Lakewood,
USA) with a subsequent incubation with anti-EpCAM MicroBeads (Miltenyi
Biotec, Germany) and a positive selection on amagnetic column. Primary cells
were cultured in BEGM (Lonza Clonetics, The Netherlands) in fully humidified
air containing 5% of CO2 at 37
C.
Primary epithelial cells and NCI-H292 cell line were cultured to 80% con-
fluence and rested for 24 hr in RPMI 1640 medium containing 100 U/ml of
penicillin and 100 mg/ml of streptomycin. Cells were then stimulated with
20 mg/ml of polyinosinic:polycytidylic acid [poly(I:C)], 0.5 mM CpG-ODN,
20 mg/ml peptidoglycan (PGN+), or 1 mg/ml Flagellin diluted in RPMI. Flagellin,
R848, and CpG were purchased from InvivoGen (USA) and poly(I:C) and
PGN from Sigma Aldrich (Germany). 1, 2, 4, 6 hr and/or 8, 16, and 24 hr after
stimulation, cells were collected for RNA extraction. All stimulation experi-
ments were performed in triplicate.
Isolation of ILCs from Peripheral Blood and Nasal Polyps
Polyp tissues were cut into fine pieces and digested for 30–45min at 37Cwith
Liberase TM (125 mg/ml) and DNase I (200 mg/ml) (both from Roche). Alterna-
tively, cells were isolated by mechanically disrupting the tissue with theStomacher 80 Biomaster (Seward). The cell suspensions were filtered through
a 70 mm nylon mesh. Peripheral mononuclear cells (PBMCs) were isolated on
Lymphoprep (Nycomed) or Ficoll-Paque Plus (GE Healthcare). PBMCs were
further depleted of T, B, and NK cells and monocytes by labeling with FITC-
conjugated CD3, CD14, CD16, and CD19 antibodies (clones described below)
and anti-FITC microbeads (Miltenyi). Depletion of lineage-positive cells was
performed with a LD column (Miltenyi). For flow cytometric sorting, lin-
depleted cells from buffy coats or total single cell suspensions from nasal
polyps were stained with the following antibody mix (clone name within
brackets): Fluorescein isothiocyanate (FITC)-conjugated anti-CD1a (HI149),
CD3 (OKT3), CD11c (3.9), CD14 (HCD14), CD16 (3G8), CD19 (HIB19), CD34
(581), CD94 (DX22), CD123 (6H6), FcER1a (AER-37); phycoerythrin (PE)-anti-
NKp44 (P44-8), peridinin chlorophyll protein-cyanine 5.5-conjugated anti-
CD117 (104D2) (all from Biolegend), FITC-conjugated anti-CD4 (RPA-T4),
CD56 (NCAM16.2), TCRab (IP26), TCRgd (B1), Alexa Fluor-647 (AF647)-
conjugated anti-CRTH2 (CD294; BM16), allophycocyanin (APC)-cyanine 7
(Cy7) anti-CD45 (2D1) and isotypes PE, APC, PECy7 (X40) (all from Beckton
Dickinson), PE-Cy7 anti-human CD127 (R34.34) (Beckman Coulter), FITC-
conjugated anti-human BDCA2 (CD303; AC144; Milenyi). LineageCD127+
CRTH2+ ILCs from nasal polyps and LineageCD127+CD117CRTH2+ ILCs
or NK cells (CD3CD56dim) from peripheral blood were sorted on a FACSAria
(BD) toR98% purity.
For phenotyping, cells were also stained with PE-conjugated anti-GATA3
(TWAJ) (eBioscience) according to the manufacturer’s instructions. For
FACS phenotype analysis, data were acquired on an LSRFortessa (BD) and
analyzed with FlowJo software (TreeStar, Inc.).
Establishment of Primary ILC Cell Lines
LinCD127+CRTH2+ ILC2s and LinCD127+CRTH2NKp44 ILCs were
cultured in Yssel’s Medium (AMC, in-house made) supplemented with 1%
Human AB Serum (Invitrogen). Cells were expanded with a feeder mixture,
composed by irradiated allogeneic PBMCs (25 Gy), irradiated JY EBV-trans-
formed B cells (50 Gy), 1 mg/ml PHA (Oxoid), and 100 U/ml IL-2 (Novartis).
IL-2 was replenished every 23 days. NK cells were expanded with the
same protocol. Expanded LinCD127+CRTH2+ cells are referred to as ILC2
cell lines and were used for experiments within 3 weeks of primary isolation.
Retroviral Constructs and Transductions
For overexpression of GATA3, the retroviral construct pLZRS-GATA3-IRES-
GFP was used according to previous descriptions (Dontje et al., 2006). For
expression of inducible STAT5 and STAT3, cells were transduced with
LZRS-STAT5-ER-IRES-GFP or LZRS-STAT3-ER-IRES-GFP, respectively, as
described before (Scheeren et al., 2005). Control virus was LZRS-IRES-GFP.
For GATA3 silencing, we used pSINSUPER-pol3-GATA3i (position 308) and
pSINSUPER-pol3-GATA3i (position 1274) retroviral constructs. Control virus
was pSINSUPER-pol3. For virus production, constructs were transfected
into Phoenix-GalV packaging cells as described before (Scheeren et al.,
2005). For transduction, ILCs were transferred to plates coated with retronec-
tin (50 mg/ml, Takara, Kyoto, Japan) and incubated with virus supernatants for
6 hr. To induce nuclear translocation of ER-tagged STAT3 and STAT5, cells
were treated with 1 mM 4-hydroxytamoxifen (4HT; Sigma-Aldrich, St Louis,
MO, USA) for 2 days.
Cytokine Stimulation of Fresh ILC2s and Cell Lines
To test cytokine production from fresh cells, LinCD127+CRTH2+ ILCs were
plated at a density of 1.5–2 3 104 cells/ml in 96-well plates and stimulated for
4 days with IL-2 (1–10 U/ml, Novartis), IL-2 (1–10 U/ml) plus IL-25 (50 ng/ml;
R&D Systems), IL-33 (50 ng/ml; R&D Systems), or TSLP (50 ng/ml; R&D
Systems). ILC2 cell lines were seeded at 1.3 3 105 cells/ml, rested without
cytokines for 24 hr, and stimulated with IL-2, IL-25, IL-33, TSLP (R&D), or
combinations of these cytokines for 4 days. Transduced cells were sorted
as GFP+ (untransduced cells as GFP) on day 3 after transduction, plated
at a density of 2–5 3 104 cells/ml in 96-well plates, and stimulated for
4 days with IL-2 (1 U/ml) or IL-2 (1 U/ml) plus IL-33 and TSLP (50 ng/ml;
R&D Systems). Multiple cytokine detection (see Table S1) in the supernatants
was performed with the MILLIPLEX MAP Human Cytokine/Chemokine Panel
(Merck Millipore) and the Biorad Bioplex-200 analysis instrument, all accord-
ing to the manufacturers’ instructions. The Bioplex Manager 4.1 softwareImmunity 37, 649–659, October 19, 2012 ª2012 Elsevier Inc. 657
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analyzed with ELISA (Sanquin).
Intracellular Cytokine and Transcription Factor Staining
Intracellular cytokine staining was performed on ex vivo expanded cell lines
(0.5–2 3 105 cells/ml) stimulated for 6 hr with 10 ng/ml PMA (Sigma) and
500 nM ionomycin (Merck) in the presence of Golgiplug (BD) for the final 4 hr
of culture. Cell permeabilization, staining, and subsequent washings were per-
formedwith the Cytofix/cytoperm kit (BD). The following antibodieswere used:
APC-conjugated anti-IL-13 (JES10-5A2, BioLegend), APC-conjugated IL-17
(BL168, BioLegend), PE-conjugated anti-IL-22 (142928, R&D), and anti-
IFN-g (B27, BD Bioscience).
Intracellular GATA3 was analyzed in ex vivo expanded cell lines or
transduced cells stimulated for 4 days with IL-2 (1 U/ml), IL-7, IL-33, TSLP
(all 50 ng/ml, R&D), or combinations of these cytokines. GATA3 staining was
performed with a GATA3 (TWAJ) (eBioscience) antibody according to the
manufacturer’s instructions. For cell proliferation analysis, cells were incu-
bated for 30 min at 37C with 1 mM of CellTrace Violet stain (Invitrogen) prior
to cytokine stimulation and GATA3 staining as described above.
Intracellular staining for pSTAT5 was done on ex vivo expanded cell
lines after 15–20 min of incubation at 37C with IL-2 (1–10 U/ml), IL-7, IL-15,
IL-33, TSLP (all 50 ng/ml, R&D), or combinations of these cytokines. This
was followed by addition of fixation/permeabilization reagent (BD) and subse-
quent fixation in ice-cold methanol. Staining was done with an Alexa 647-
conjugated monoclonal antibody specific for phosphorylated STAT5 (pY694,
clone 47) or PE-conjugated anti-STAT3 (pY705, clone 4/P-STAT3) (both
from BD). Cells were incubated for 60 min on ice and subsequently washed
with the permeabilization buffer of the fixation/permeabilization kit (BD).
Data were acquired on an LSRFortessa or LSRII (BD) and analyzed with
FlowJo software (Tree Star, Inc.).
Quantitative Real-Time PCR
For nasal epithelial cells and H292 cell lines, total RNAwas extracted by TRIzol
(Life Technologies, USA) and chloroform (Merck, Germany) phase separation
method and additionally purified with nucleospin RNA II kit (Machery-Nagel)
according to the manufacturer’s protocol. The MBI Fermentas first strand
cDNA synthesis kit (Fermentas GmbH, Germany) was used to synthesize
cDNA according to the manufacturer’s instructions. PCRs were performed
in Bio-Rad iCycler (Bio-Rad, France) with a mRNA-specific TaqMan
gene expression assay (Applied Biosystems, USA) for TSLP-long form
(Hs01572933_m1) or with IQ SYBR Green Supermix (Bio-Rad, France) using
the primers described in Table S1. Expression levels of evaluated genes
were calculated with the comparative DCt method. Each value was corrected
for the expression of the housekeeping gene and compared to the control
(unstimulated) condition.
For all other samples, RNA isolation, cDNA synthesis, and PCR was per-
formed as previously described (Mjo¨sberg et al., 2011). Additional primers
used for PCR are described in Table S2.
Statistical Analysis
Student’s t test or Wilcoxon’s matched pairs test was used to determine
the statistical differences between the data sets. *p % 0.05, **p % 0.01,
yp = 0.06, yy0.07, ns, not significant.
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